Agents for Parenteral Antibiotic Treatment of CSF Shunt Infections
| Isolated Microorganism | First-line antibiotics | Other choices |
| Staphylococcus epidermidis | Vancomycin, linezolid | Oxacillin, nafcillin |
| Staphylococcus aureus | Vancomycin, linezolid | Oxacillin, nafcillin |
| Enterococcus faecalis | Vancomycin, penicillin | Ampicillin |
| Escherichia coli | Cefotaxime, meropenem | Gentamycin, amikacin |
| Klebsiella pneumoniae | Cefotaxime, meropenem | Gentamycin, amikacin |
| Proteus sp. | Cefotaxime, ceftazidime | Gentamycin, amikacin |
| Pseudomonas sp. | Ceftazidime + amikacin | Meropenem, cefipime |
| Haemophilus influenzae | Cefotaxime, ampicillin | Ceftriaxone |
| Streptococcus pneumoniae | Penicillin G, cefotaxime, ceftriaxone | Vancomycin, ampicillin |
| Neisseria meningitidis | Penicillin G, ampicillin | Cefotaxime, ceftriaxone |
| Propionibacterium acnes | Penicillin G | Doxycycline |
| Corynebacterium sp. | Penicillin G | Doxycycline |
| Candida sp. | Amphotericin B | Caspofungine, voriconazole |
Agents for Intraventricular Treatment of CSF Shunt Infections
| Antimicrobial Agent | Dose |
| Gentamycin | 2–8 mg/day |
| Vancomycin | 4–20 mg/day |
| Amphotericin B | 0.1–0.5 mg/day |
| Miconazole | 20 mg/day |
Modified from Kaufman (89)